Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "SKELETAL MUSCLE RYANODINE RECEPTOR" patented technology

In skeletal muscle, activation of ryanodine receptors occurs via a physical coupling to the dihydropyridine receptor (a voltage-dependent, L-type calcium channel), whereas, in cardiac muscle, the primary mechanism of activation is calcium-induced calcium release, which causes calcium outflow from the sarcoplasmic reticulum.

Screening method

The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca<2+>-channels or on the [<3>H]-ryanodine receptors of the retinal pigment epithelium.
Owner:TRIER KLAUS

Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure

InactiveUS20060293266A1Effective treatmentBiocideOrganic active ingredientsPhosphodiesteraseRyanodine receptor complex
The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Transgenic animal model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and use thereof

The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2).Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.
Owner:PRIORI SILVIA G +1

Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) and uses thereof

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Ryanodine receptor blockers for treating pain

The present invention provides a method of preventing or ameliorating pain in a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action causing said pain, an effective amount of a ryanodine antagonist, such as dantrolene, to inhibit or prevent pain.
Owner:ALLERGAN INC

Method and special primer of method for fast identifying plutella xylostella ryanodine receptor gene mutation

InactiveCN102952889ATimely adjustment of prevention and control strategiesHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationAgricultural scienceOpen reading frame
The invention discloses a method and a special primer of the method for fast identifying the plutella xylostella ryanodine receptor gene mutation. The invention provides a specific primer combination, which consists of a single chain DNA (deoxyribonucleic acid) molecule shown as a sequence 1 of a sequence table, a single chain DNA molecule shown as a sequence 2 of the sequence table and a single-chain DNA molecule shown as a sequence 3 of the sequence table. The specific primer combination can be used for the following (a) or (b): (a) the specific primer combination can be used for identifying whether plutella xylostella generates the G4899E mutation of the ryanodine receptor gene or not, and the G4899E mutation of the ryanodine receptor gene refers to that an open reading frame of the ryanodine receptor gene is mutated into A from G in the 14696 locus nucleotide of the 5' tail end; and (b) the specific primer combination is used for the auxiliary identification of the resistance of plutella xylostella on bisamide pesticides. The specific primer combination and the application of the specific primer combination have the important significance in the aspects of monitoring the resistance gene frequency of plutella xylostella field populations on the bisamide pesticides and the bisamide pesticide resistance generation and development trend of the plutella xylostella field populations, timely regulating the plutella xylostella preventing and control strategy, guiding the reasonable pesticide use and delaying the resistance development.
Owner:CHINA AGRI UNIV

Method and special primer of method for fast identifying plutella xylostella ryanodine receptor gene mutation

InactiveCN102952889BTimely adjustment of prevention and control strategiesHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationBiotechnologyOpen reading frame
The invention discloses a method and a special primer of the method for fast identifying the plutella xylostella ryanodine receptor gene mutation. The invention provides a specific primer combination, which consists of a single chain DNA (deoxyribonucleic acid) molecule shown as a sequence 1 of a sequence table, a single chain DNA molecule shown as a sequence 2 of the sequence table and a single-chain DNA molecule shown as a sequence 3 of the sequence table. The specific primer combination can be used for the following (a) or (b): (a) the specific primer combination can be used for identifying whether plutella xylostella generates the G4899E mutation of the ryanodine receptor gene or not, and the G4899E mutation of the ryanodine receptor gene refers to that an open reading frame of the ryanodine receptor gene is mutated into A from G in the 14696 locus nucleotide of the 5' tail end; and (b) the specific primer combination is used for the auxiliary identification of the resistance of plutella xylostella on bisamide pesticides. The specific primer combination and the application of the specific primer combination have the important significance in the aspects of monitoring the resistance gene frequency of plutella xylostella field populations on the bisamide pesticides and the bisamide pesticide resistance generation and development trend of the plutella xylostella field populations, timely regulating the plutella xylostella preventing and control strategy, guiding the reasonable pesticide use and delaying the resistance development.
Owner:CHINA AGRI UNIV

Ntranasal dantrolene administration for treatment of alzheimer's disease

PendingUS20220354827A1Reduce releaseImproving and slowing declineOrganic active ingredientsNervous disorderRyanodine receptorSynaptogenesis
Methods for inhibiting impaired neurogenesis and / or synaptogenesis in neurons in a subject with or suspected of having Alzheimer's Disease (AD), methods for improving and / or slowing the decline of cognitive function after onset of neuropathology and cognitive dysfunction, which neuropathology and cognitive dysfunction are caused by AD, methods for improving and / or slowing the decline of memory before onset of symptoms of AD, methods for increasing concentration and duration of dantrolene in the brain, and methods for improving and / or slowing the decline of memory after onset of symptoms of AD, the methods comprising intranasally administering to a subject in need thereof an amount of a pharmaceutical composition comprising dantrolene effective to inhibit over-activation of N-methyl-D-aspartate (NMVDA) receptor and / or ryanodine receptor (RyR). Methods further comprise administering a therapeutically effective amount of a glutamate receptor antagonist to the subject.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products